CannPal primed to test flagship cannabis pain relief drug for animals

CannPal primed to test flagship cannabis pain relief drug for animals

After securing key export permits from the Canadian government, CannPal Animal Therapeutics (ASX: CP1) has received its first batch of cannabis oil formulations in Australia.

The oils, which will be used in clinical trials for CannPal's lead drug candidate CPAT-01, arrived in Sydney and are currently in transit to a purpose-built research facility.

CPAT-01 is a cannabis-derived medicine which is being developed as a treatment for pain in companion animals, an alternative to non-steroidal anti-inflammatory medications which often incur a long list of side effects.

CannPal is set to test the drug in two phases, with a total of 59 dogs enrolled for treatment beginning on April 2.

CannPal founder and managing director Layton Mills says the global market for pain treatment in companion is worth more than US$1.4 billion, one which his company is now closer to cornering.

"CannPal is delighted to have successfully imported the oils for our first clinical trial for CPAT-01," says Mills.

"With the oils now in Australia and the dog selection complete we are all set to commence the live phase of our clinical research.

"Our study is the first of its kind in Australia and is one that we hope will result in the creation of a safe, efficacious pain treatment for companion animals that will meet full regulatory approval."

The company aims to treat common conditions in animals including arthritis, cancer and tumours, using safe solutions to alleviate symptoms including nausea, loss of appetite, depression and internal bleeding.

At the beginning of 2018, CannPal received its medical cannabis import license from the Office of Drug Control in Australia.

The company listed on the ASX in late October 2017 and has since gained small-medium enterprise (SME) status by the European Medicines Agency.

This opens the company up to administrative and financial assistance for the development of its drugs in Europe.

At the time of writing (11:03am AEST) CannPal shares dipped a slight 3.9 per cent to trade at $0.24.

Photo courtesy of Captain Cruise @captaincuise on Instagram.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

How communications technology can raise the bar on customer service, employee experience
Partner Content
From capturing feedback early to providing messages with a higher rate of cut-through, ...
Advertisement

Related Stories

Car subscription software company Loopit eyes global markets after $3.6m seed round

Car subscription software company Loopit eyes global markets after $3.6m seed round

In a bid to enter new global markets and capitalise on the growing ...

Fashion-tech startup Citizen Wolf uses data to tailor tees, alleviate landfill

Fashion-tech startup Citizen Wolf uses data to tailor tees, alleviate landfill

As a consequence of our addiction to fast fashion, Australia sends ...

Apollo to divest large share of motorhome fleet to get Tourism Holdings merger over the line

Apollo to divest large share of motorhome fleet to get Tourism Holdings merger over the line

In an effort to appease Australian and New Zealand regulator concer...

Dexus awards John Holland building contract in $2.1b Waterfront Brisbane project

Dexus awards John Holland building contract in $2.1b Waterfront Brisbane project

After securing an $830 million contract from Dexus (ASX: DXS), Melb...